246 related articles for article (PubMed ID: 28639216)
1. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
Boehler M; Bruderer S; Ulč I; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):115-120. PubMed ID: 28639216
[TBL] [Abstract][Full Text] [Related]
2. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Kaufmann P; Niglis S; Bruderer S; Segrestaa J; Äänismaa P; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2015 Oct; 80(4):670-7. PubMed ID: 25851691
[TBL] [Abstract][Full Text] [Related]
3. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
Baldoni D; Bruderer S; Muhsen N; Dingemanse J
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Bruderer S; Hurst N; Kaufmann P; Dingemanse J
Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
9. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
Kaufmann P; Hurst N; Astruc B; Dingemanse J
Eur J Clin Pharmacol; 2017 Feb; 73(2):151-156. PubMed ID: 27885399
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J
Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071
[TBL] [Abstract][Full Text] [Related]
11. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
[TBL] [Abstract][Full Text] [Related]
12. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
14. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang IM
Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
17. A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers.
Pan L; Belloni P; Ding HT; Wang J; Rubino CM; Putnam WS
Adv Ther; 2017 Sep; 34(9):2071-2082. PubMed ID: 28808905
[TBL] [Abstract][Full Text] [Related]
18. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist.
Hoch M; Darpo B; Remenova T; Stoltz R; Zhou M; Kaufmann P; Bruderer S; Dingemanse J
Drug Des Devel Ther; 2015; 9():175-85. PubMed ID: 25552906
[TBL] [Abstract][Full Text] [Related]
19. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
